Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713 · LY4337713

Radiopharmaceutical · Kills target cells, directed at fibroblast activation protein (FAP) · developed by ELI LILLY &

Phase 1 Most advanced trial
LLY Developer

What is Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713?

Lutetium Lu 177-labeled FAP-targeting ligand LY4337713 is a radioconjugate that binds fibroblast activation protein (FAP), a cell surface protein overexpressed on cancer-associated fibroblasts in the tumor microenvironment. It delivers beta radiation from lutetium Lu 177 to these fibroblasts. It is being studied in advanced solid tumors, including ovarian, breast, pancreatic, colorectal, esophageal, gastric and biliary cancers.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
LY4337713
Drug type
Radiopharmaceutical
Targets
fibroblast activation protein (FAP)
Mechanism
Kills target cells, directed at fibroblast activation protein (FAP)
Therapy area
Oncology
Developer
ELI LILLY & (LLY)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

Conditions studied

Advanced Solid TumorsBreast NeoplasmsCholangiocarcinomaColorectal NeoplasmsEsophageal NeoplasmsOvarian NeoplasmsPancreatic Intraductal NeoplasmsStomach Neoplasms

Other drugs acting on FAP

More from ELI LILLY &

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the LLY page.

Follow LLY, the company behind Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713

See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LLY catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.